Transplant recipients are at an increased risk of developing iatrogenic KS due to the immunosuppressive medications required to prevent organ rejection. These drugs, while critical for maintaining the health of the transplanted organ, also weaken the body's immune response, making it easier for infections like HHV-8 to thrive and cause cancerous growths. The balance between preventing rejection and minimizing cancer risk is delicate and requires careful management.
